The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers has never been more essential. Demand for information early in drug development continues to increase.
In the first of a two-part series on early engagement with payers, Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Allen Lising, Managing Director of FormularyDecisions at Xcenda to discuss how this platform is used to facilitate the early and ongoing exchange of information between qualified, active payers and life sciences companies.
The conversation is captured in a recent blog posting on tHEORetically Speaking where Peeples and Lising explore insights Xcenda has uncovered to help manufacturers understand what payers want, when they want it, and how can it be delivered in a “contactless” environment.
Read the blog here. (Source: Lising A, Peeples P. tHEORetically Speaking blog, 08/19/2020).